Literature DB >> 8761898

Hyperinsulinaemia as a predictor of hypertension: an 11-year follow-up study in Japan.

M Tsuruta1, R Hashimoto, H Adachi, T Imaizumi, G Nomura.   

Abstract

OBJECTIVE: To examine the hypothesis that hyperinsulinaemia is associated with the development of borderline hypertension or hypertension.
DESIGN: Blood pressure status in non-obese normotensives (< 140/90 mmHg, n = 135) people were re-examined after 11 years after the baseline examination. Participants were selected from a 1981 population-based health examination and had a high blood glucose level or more than a trace of glucose in their urine. Out of 319 people recruited for further examination of glucose tolerance status, 135 normotensive participants with body mass index < 26 kg/m2 and without diabetes according to World Health Organization criteria were re-examined at the follow-up survey.
RESULTS: Sixty-two (46%) out of 135 normotensive participants were hypertensive (defined as blood pressure > or = 140/90 mmHg) or receiving antihypertensive medication (n = 8) at the follow-up survey. Significant associations between the development of hypertension and baseline parameters were observed for systolic and diastolic blood pressure, serum triglycerides, high-density lipoprotein (HDL)-cholesterol, fasting and 60 min post-load insulin levels, and the sum of insulin concentrations from fasting to 180 min after glucose challenge after adjustments for age and sex. Odds ratios (95% confidence intervals) for the future development of hypertension between the highest and the lowest tertiles of insulin levels were 4.06 (1.40-11.76) for fasting insulin, 4.25 (1.45-12.45) for 60 min post-glucose load insulin, and 3.88 (1.34-11.20) for the sum of insulin concentrations, after adjustment for age, sex, systolic blood pressure, body mass index and alcohol consumption. Further adjustments for serum triglycerides and serum creatinine did not affect the insulin-hypertension relationship.
CONCLUSION: The present study suggests that hyperinsulinemia is significantly related to the development of hypertension in non-obese and non-diabetic Japanese people.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8761898

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  6 in total

1.  Insulin resistance and risk of incident hypertension among men.

Authors:  Tai-Shuan Lai; Gary C Curhan; John P Forman
Journal:  J Clin Hypertens (Greenwich)       Date:  2009-09       Impact factor: 3.738

2.  Sex-specific relations between fasting insulin, insulin resistance and incident hypertension: 8.9 years follow-up in a Middle-Eastern population.

Authors:  B Arshi; M Tohidi; A Derakhshan; S Asgari; F Azizi; F Hadaegh
Journal:  J Hum Hypertens       Date:  2014-08-28       Impact factor: 3.012

3.  Characteristics of type 2 diabetes in terms of insulin resistance in Korea.

Authors:  Jong-Suk Park; Chul-Sik Kim; Joo-Young Nam; Dol-Mi Kim; Min-Ho Jo; Jina Park; Chul-Woo Ahn; Bong-Soo Cha; Sung-Kil Lim; Kyung-Rae Kim; Hyun-Chul Lee; Kap-Bum Huh
Journal:  Yonsei Med J       Date:  2005-08-31       Impact factor: 2.759

4.  Fasting insulin concentrations and incidence of hypertension, stroke, and coronary heart disease: a meta-analysis of prospective cohort studies.

Authors:  Pengcheng Xun; Ying Wu; Qianchuan He; Ka He
Journal:  Am J Clin Nutr       Date:  2013-10-16       Impact factor: 7.045

5.  Impact of 3-year changes in fasting insulin and insulin resistance indices on incident hypertension: Tehran lipid and glucose study.

Authors:  Aidin Baghbani-Oskouei; Maryam Tohidi; Mitra Hasheminia; Fereidoun Azizi; Farzad Hadaegh
Journal:  Nutr Metab (Lond)       Date:  2019-11-09       Impact factor: 4.169

6.  The relationship between lipid risk score and new-onset hypertension in a prospective cohort study.

Authors:  Hankun Xie; Qian Zhuang; Jialing Mu; Junxiang Sun; Pengfei Wei; Xianghai Zhao; Yanchun Chen; Jiayi Dong; Changying Chen; Lai Wei; Yunjie Yin; Song Yang; Chong Shen
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-28       Impact factor: 6.055

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.